|This article is an orphan, as no other articles link to it. Please introduce links to this page from ; try the Find link tool for suggestions. (February 2009)|
It is manufactured by Oxford BioMedica, who plan to start European Phase I and Phase II clinical trials in 2007. Animal trials have been a success, with dopamine levels restored without the side effects associated with other current treatments for Parkinson's, in particular, without the jerky involuntary movements associated with current drugs.
Mechanism of Action
Prosavin uses Oxford BioMedica's Lentivector delivery system to transfer three genes, aromatic amino acid dopa decarboxylase, tyrosine hydroxylase and GTP-cyclohydrolase 1, to the striatum in the brain, reprogramming transduced cells to secrete dopamine. http://www.oxfordbiomedica.co.uk/prosavin-r/
- Oxford BioMedica. Drug Information Page. Retrieved on March 29, 2007.
- Daily Telegraph. Investor Information. Retrieved on March 29, 2007.
- Ben Hirschler (2009-10-14). "Long-term monkey tests back Oxford's gene therapy". Reuters. Retrieved 2009-10-14.
- Oxford BioMedica . Drug Advanced Information Page. Retrieved on April 5, 2007.